On November 16, Moderna claimed the latest breakthrough with its vaccine candidate mRNA-1237, deemed 94.5% effective against COVID-19 — just within striking distance of Pfizer’s vaccine, which demonstrated 95% efficacy according to the pharma giant.
Services
Links
Sign up to receive first access to our reports, the latest patent news, and other updates —
all delivered to your inbox.
Sign up now to receive monthly patent news, analysis and free insight reports.
We don’t spam, we promise.
Disclaimer:
1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership.
2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.